Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases

Clinical Genitourinary Cancer

Volumn 11, Issue 1, 2013, Pages 20-26

  Nilsson, Sten ^a   Franzén, Lars ^b,o   Parker, Christopher ^c   Tyrrell, Christopher ^d   Blom, René ^e   Tennvall, Jan ^f   Lennernäs, Bo ^g,p   Petersson, Ulf ^h   Johannessen, Dag C ⁱ   Sokal, Michael ^j   Pigott, Katharine ^k   O'Bryan Tear, Charles Gillies ^l   Thuresson, Marcus ^m   Bolstad, Bjørg ^l   Bruland, Øyvind S ⁿ  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sundsvall Härnösand County Hospital   (Sweden)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h Centrallasaretteti Västerås   (Sweden)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^k ROYAL FREE HOSPITAL   (United Kingdom)

^l Algeta AS   (Norway)

^m STATISTICON AB   (Sweden)

ⁿ UNIVERSITY OF OSLO   (Norway)

^o UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^p LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Alpha pharmaceutical; Castration resistant prostate cancer; Overall survival; Targeted alpha emitter

Indexed keywords

PLACEBO; RADIOISOTOPE; RADIUM 223; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PALLIATIVE CARE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME;

EID: 84874543674     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.07.002     Document Type: Article

References (28)

1. G.R. Mundy Metastasis to bone: causes, consequences, and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
2. P.H. Lange, R.L. Vessella Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone Cancer Metastasis Rev 17 1999 331 336
3. D. Goltzman Mechanisms of the development of osteoblastic metastases Cancer 80 1997 1581 1587
4. B.F. Boyce, T. Yoneda, T.A. Guise Factors regulating the growth of metastatic cancer in bone Endocr Relat Cancer 6 1999 333 347
5. A. Lipton Implications of bone metastases and the benefits of bone-targeted therapy Semin Oncol 37 2010 S15 S29
6. H.I. Scher, K. Fizazi, F. Saad Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study J Clin Oncol 30 2012 abstract LBA1
7. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
8. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
9. J.S. de Bono, S. Oudard, M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
10. D.C. Danila, M.J. Morris, J.S. de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
11. G. Attard, A.H. Reid, R. A'Hern Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
12. S. Adami Bisphosphonates in prostate carcinoma Cancer 80 1997 1674 1679
13. M.R. Smith, F. Saad, B. Egerdie Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer J Urol 182 2009 2670 2675
14. M.R. Smith, B. Egerdie, T.N. Hernandez Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
15. E.B. Silberstein Systemic radiopharmaceutical therapy of painful osteoblastic metastases Semin Radiat Oncol 10 2000 240 249
16. G. Henriksen, K. Breistøl, O.S. Bruland Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model Cancer Res 62 2002 3120 3125
17. O.S. Bruland, S. Nilsson, D.R. Fisher High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12 2006 6250s 6257s
18. V.J. Lewington Bone-seeking radionuclides for therapy J Nucl Med 46 suppl 1 2005 38S 47S
19. K. Liepe Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer Curr Opin Investig Drugs 10 2009 1346 1358
20. M.R. McDevitt, G. Sgouros, R.D. Finn Radioimmunotherapy with alpha-emitting nuclides Eur J Nucl Med 25 1998 1341 1351
21. C. Kerr (223)Ra targets skeletal metastases and spares normal tissue Lancet Oncol 3 2002 453
22. Y. Li, P.J. Russell, B.J. Allen Targeted alpha-therapy for control of micrometastatic prostate cancer Expert Rev Anticancer Ther 4 2004 459 468
23. G. Henriksen, D.R. Fisher, J.C. Roeske Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice J Nucl Med 44 2003 252 259
24. S. Nilsson, R.H. Larsen, S.D. Fosså First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 2005 4451 4459
25. S. Nilsson, L. Franzén, C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
26. S. Nilsson, P. Strang, A.K. Aksnes A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer Eur J Cancer 48 2012 678 686
27. C. Parker, D. Heinrich, J.M. O'Sullivan Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) Ann Oncol 22 suppl 5 2011 v10 v18 (abstract 1LBA)
28. S. Halabi, E.J. Small, P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 Errata J Clin Oncol 22 2004 3434